InMode (NASDAQ:INMD) Updates FY25 Earnings Guidance

InMode (NASDAQ:INMD) issued an update on its FY25 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $1.95-$1.99 for the period, compared to the consensus earnings per share estimate of $1.98. The company issued revenue guidance of $395-$405 million, compared to the consensus revenue estimate of $413.47 million.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Needham & Company LLC reissued a “hold” rating on shares of InMode in a report on Tuesday. Barclays raised their target price on shares of InMode from $26.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, BTIG Research assumed coverage on shares of InMode in a report on Thursday, October 17th. They set a “buy” rating and a $25.00 target price for the company. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $23.00.

InMode Trading Up 0.6 %

INMD stock traded up $0.11 during trading on Thursday, reaching $18.07. 141,062 shares of the stock were exchanged, compared to its average volume of 868,796. The business has a 50 day moving average price of $17.41 and a 200-day moving average price of $17.20. InMode has a 1 year low of $14.87 and a 1 year high of $26.80. The firm has a market capitalization of $1.52 billion, a price-to-earnings ratio of 9.77 and a beta of 2.13.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.